Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genta Incorporated

Criteria

• Any age

• Must have received at least one chemotherapy regimen that included fludarabine

• Measurable disease

• At least 3 weeks since biological therapy or radiation therapy for chronic lymphocytic leukemia

• No previous stem cell transplantation

• At least 3 weeks since surgery